Humacyte Inc (HUMA) Stock Price, Quote & News

Company Profile

Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 313 9633

Website: www.humacyte.com

Address:

2525 East North Carolina Highway 54, Durham, United States

Zenlama Aug. 19 at 2:52 PM

$HUMA I added more today, could have done so earlier, but have more confidence today. GLTA

0 · Reply

MarketPro Aug. 19 at 2:50 PM

$HUMA Been awhile since we've seen the chart do this....

1 · Reply

nashstocks Aug. 19 at 2:35 PM

$HUMA Patience will pay on this one.

0 · Reply

Rybod30 Aug. 19 at 2:17 PM

$HUMA Darn, $.66, better than nada..

0 · Reply

crowbaby333 Aug. 19 at 2:08 PM

$HUMA

0 · Reply

Rybod30 Aug. 19 at 1:47 PM

$HUMA $.05 flag on 5min🤷‍♂️😬….

0 · Reply

Rybod30 Aug. 19 at 1:44 PM

$HUMA She needs to get $1 back, DOD contract would obviously do it😬🤷‍♂️…..

0 · Reply

Jamieraffle Aug. 19 at 1:42 PM

$HUMA oooo an 11% spike, hopefully management give us more shitty news today so we lose all hope again 🙄 Being transparent, I really hope this can rally like we know it should

0 · Reply

Bob584 Aug. 19 at 1:38 PM

$HUMA "Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte's 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation." First company to receive RMAT & has Fast Track designation. Huma holds global patents until 2041 for esophagus and urinary tract replacement. The upside potential in the next few years is nearly unfathomable. Recent price depression from Fresenius was expected. Institutions are loading up big

0 · Reply

APman Aug. 19 at 1:26 PM

$HUMA Their science is undeniable.

0 · Reply

Humacyte publishes V007 results in The Lancet Digital Health

Aug 19, 2026, 8:00 AM EDT - 2 hours ago

Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results

Aug 18, 2026, 8:00 AM EDT - 1 day ago

Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”

2026-08-17T09:58:11.000Z - 2 days ago

Humacyte reports Q2 EPS (16c), consensus (10c)

2026-08-17T07:52:22.000Z - 2 days ago

Humacyte price target lowered to $1 from $2 at Benchmark

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Humacyte Earnings Call Transcript: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Humacyte Earnings release: Q2 2026

Aug 12, 2026, 8:00 AM EDT - 7 days ago

Humacyte Quarterly report: Q2 2026

Aug 12, 2026, 7:00 AM EDT - 7 days ago

Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update

Aug 10, 2026, 12:27 PM EDT - 8 days ago

Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA

Aug 7, 2026, 8:00 AM EDT - 12 days ago

Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026

2026-07-27T12:25:48.000Z - 23 days ago

Humacyte announces FDA acceptance of CTEV IND application

Jul 27, 2026, 8:00 AM EDT - 23 days ago

Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting

Jul 14, 2026, 8:00 AM EDT - 5 weeks ago

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

2026-06-17T12:32:32.000Z - 2 months ago

Humacyte price target lowered to $1.25 from $1.50 at TD Cowen

Jun 16, 2026, 3:00 PM EDT - 2 months ago

Humacyte Slides: Corporate presentation

Jun 15, 2026, 5:00 PM EDT - 2 months ago

Humacyte Transcript: Study result

Jun 15, 2026, 5:00 PM EDT - 2 months ago

Humacyte Press release: Study result

Jun 15, 2026, 8:00 AM EDT - 2 months ago

Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual Meeting

2026-06-11T13:47:07.000Z - 2 months ago

Humacyte price target raised to $4 from $3 at H.C. Wainwright

2026-06-11T01:35:07.000Z - 2 months ago

Humacyte 47.62M share Spot Secondary priced at $1.05

Jun 10, 2026, 9:08 PM EDT - 2 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

2026-06-10T22:15:08.000Z - 2 months ago

Humacyte TBA Spot Secondary; price range $1.05-$1.15

2026-06-10T20:14:24.000Z - 2 months ago

Humacyte announces V012 study of ATEV meets primary endpoint

2026-06-10T20:10:11.000Z - 2 months ago

Humacyte announces common stock offering, no amount given

Jun 10, 2026, 4:04 PM EDT - 2 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

Jun 10, 2026, 4:01 PM EDT - 2 months ago

Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access Patients

Jun 9, 2026, 8:00 AM EDT - 2 months ago

Humacyte Transcript: AGM 2026

Jun 5, 2026, 3:52 PM EDT - 2 months ago

Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-06-01T11:58:24.000Z - 2 months ago

Humacyte price target raised to $2 from $1 at Benchmark

2026-05-26T15:23:12.000Z - 3 months ago

Humacyte announces presentation at VASA meeting on self-repair ATEV

May 26, 2026, 8:00 AM EDT - 3 months ago

Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access

2026-05-20T12:14:56.000Z - 3 months ago

Humacyte reports Symvess under contract with Strategic Acquisition Center of VA

May 20, 2026, 8:00 AM EDT - 3 months ago

Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs

2026-05-14T15:08:47.000Z - 3 months ago

Humacyte price target raised to $1.50 from $1 at TD Cowen

2026-05-13T13:00:50.000Z - 3 months ago

Humacyte reports Q1 EPS (9c), consensus (12c)

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings Call Transcript: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Earnings release: Q1 2026

May 13, 2026, 8:00 AM EDT - 3 months ago

Humacyte Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update

2026-05-12T15:32:56.000Z - 3 months ago

Humacyte names Todd Rasmussen chief surgical officer

May 12, 2026, 8:00 AM EDT - 3 months ago

Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer

May 8, 2026, 6:00 PM EDT - 3 months ago

Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA

May 8, 2026, 8:00 AM EDT - 3 months ago

Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Humacyte Transcript: KOL event

Apr 28, 2026, 8:00 AM EDT - 4 months ago

Humacyte Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 4 months ago

Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026

2026-04-24T12:33:04.000Z - 4 months ago

Humacyte realigns ex-U.S. rights to Symvess through Fresenius Medical pact

FMS

Apr 24, 2026, 8:00 AM EDT - 4 months ago

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Humacyte Appoints Jim Mercadante as Chief Commercial Officer

2026-04-21T13:26:28.000Z - 4 months ago

Humacyte announces Israeli Ministry of Health acceptance of MAA for Symvess

Apr 21, 2026, 8:00 AM EDT - 4 months ago

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Humacyte Proxy statement: Proxy filing

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Earnings Call Transcript: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Annual report: Q4 2025

Mar 27, 2026, 8:00 AM EDT - 5 months ago

Humacyte Earnings release: Q4 2025

Mar 27, 2026, 7:00 AM EDT - 5 months ago

Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Humacyte Appoints Rick McElheny as Senior Vice President of Business Development

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026

Mar 19, 2026, 8:30 AM EDT - 5 months ago

Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock

Mar 17, 2026, 8:00 AM EDT - 5 months ago

Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair

Mar 10, 2026, 1:00 PM EDT - 5 months ago

Humacyte Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 4, 2026, 10:30 AM EST - 5 months ago

Humacyte Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 6 months ago

Humacyte To Participate in Upcoming Investor Conferences

Feb 18, 2026, 8:00 AM EST - 6 months ago

Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting

Feb 9, 2026, 8:00 AM EST - 6 months ago

Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels

Jan 8, 2026, 8:00 AM EST - 7 months ago

Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications

Jan 5, 2026, 8:00 AM EST - 8 months ago

Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel

Dec 22, 2025, 8:00 AM EST - 8 months ago

Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair

Dec 16, 2025, 8:00 AM EST - 8 months ago

Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital

Nov 20, 2025, 8:00 AM EST - 9 months ago

Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results

Nov 13, 2025, 8:00 AM EST - 9 months ago

Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Earnings Call Transcript: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Quarterly report: Q3 2025

Nov 12, 2025, 8:00 AM EST - 10 months ago

Humacyte Earnings release: Q3 2025

Nov 12, 2025, 7:00 AM EST - 10 months ago

Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025, 8:00 AM EST - 10 months ago

Humacyte Announces Presentation of Positive Two-Year Results from Phase 3 Dialysis Access Trial at the American Society of Nephrology's Kidney Week 2025

Nov 6, 2025, 8:00 AM EST - 10 months ago

Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Humacyte Announces Publication of New Data Comparing Symvess™ to Autologous Vein in Extremity Arterial Trauma

Oct 7, 2025, 9:00 AM EDT - 11 months ago

Humacyte Announces Pricing of $60.0 Million Oversubscribed Registered Direct Offering

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Humacyte Announces Publication of Long-Term Results for Ukrainian Patients Treated in Real-World Combat Setting with Symvess™

Sep 29, 2025, 8:00 AM EDT - 11 months ago

Humacyte Announces Expansion of Intellectual Property for Pipeline Products with Granting of New U.S. Patent for Bioengineered Esophagus

Sep 18, 2025, 7:00 AM EDT - 11 months ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

Sep 15, 2025, 7:00 AM EDT - 1 year ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

Sep 12, 2025, 8:00 AM EDT - 1 year ago

Humacyte Registration statement: Registration Filing

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings Call Transcript: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 1 year ago

Humacyte Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 1 year ago

Humacyte Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Humacyte Announces First Symvess™ Sale to Military Treatment Facility

Jul 8, 2025, 8:00 AM EDT - 1 year ago

Humacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics Agency

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Results from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

Zenlama Aug. 19 at 2:52 PM

$HUMA I added more today, could have done so earlier, but have more confidence today. GLTA

0 · Reply

MarketPro Aug. 19 at 2:50 PM

$HUMA Been awhile since we've seen the chart do this....

1 · Reply

nashstocks Aug. 19 at 2:35 PM

$HUMA Patience will pay on this one.

0 · Reply

Rybod30 Aug. 19 at 2:17 PM

$HUMA Darn, $.66, better than nada..

0 · Reply

crowbaby333 Aug. 19 at 2:08 PM

$HUMA

0 · Reply

Rybod30 Aug. 19 at 1:47 PM

$HUMA $.05 flag on 5min🤷‍♂️😬….

0 · Reply

Rybod30 Aug. 19 at 1:44 PM

$HUMA She needs to get $1 back, DOD contract would obviously do it😬🤷‍♂️…..

0 · Reply

Jamieraffle Aug. 19 at 1:42 PM

$HUMA oooo an 11% spike, hopefully management give us more shitty news today so we lose all hope again 🙄 Being transparent, I really hope this can rally like we know it should

0 · Reply

Bob584 Aug. 19 at 1:38 PM

0 · Reply

APman Aug. 19 at 1:26 PM

$HUMA Their science is undeniable.

0 · Reply

MarketPro Aug. 19 at 12:51 PM

$HUMA HUMA is not doing a drug launch. MD adoption is slow by comparison. This publication and the article yesterday aim directly at the adoption issue. The economics work. We just need management to get their butt in gear....

3 · Reply

Rybod30 Aug. 19 at 12:49 PM

$HUMA Just a matter of time before symvess is in every trauma ward, lawsuits galore without availability, question is, will current shareholders benefit?🤷‍♂️😬…

0 · Reply

Runmaster83 Aug. 19 at 12:21 PM

$HUMA 👀 https://finance.yahoo.com/healthcare/articles/humacyte-announces-lancet-digital-health-120000234.html

0 · Reply

Runmaster83 Aug. 19 at 12:20 PM

$HUMA https://finance.yahoo.com/healthcare/articles/humacyte-announces-lancet-digital-health-120000234.html

0 · Reply

Rybod30 Aug. 19 at 12:19 PM

$HUMA Solid PRs two days in a row, wild. Slight break from the usual trend of radio silence…

0 · Reply

Merlintrader Aug. 19 at 12:13 PM

$HUMA Fresenius sold 4,709,500 shares between August 10 and August 17 under a Rule 10b5-1 plan, for 2.78 million dollars gross, with daily weighted average prices falling from 0.7249 to 0.5547. It keeps 13,603,235 shares, about 4.9 percent, and crossed below the five percent line on August 17, which ends the duty to report further sales promptly. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/humacyte-presentation-june2026-deepdive/?utm_source=stocktwits&utm_medium=social&utm_campaign=news-19ago2026

0 · Reply

charlie_twits Aug. 19 at 12:11 PM

$HUMA Are they able to publish PR without typos?

0 · Reply

Runmaster83 Aug. 19 at 12:05 PM

$HUMA 😂

1 · Reply

Fred_Sigma_Invest Aug. 19 at 2:09 AM

$HUMA Little chump @crowbaby333 is massivley butt hurt that all his childish pumping over the years lead to exactly NOTHING. "I was right about a lot!!" as the stock sits at 50 cents. I bigger dope you will not ever find.

1 · Reply

HappyEndings Aug. 18 at 10:44 PM

$HUMA https://markets.businessinsider.com/news/stocks/board-certified-vascular-and-endovascular-surgeon-performs-first-commercial-symvess-implantation-cites-bioengineered-blood-vessel-as-revolutionary-advancement-1036470130

0 · Reply

forgottenchuck Aug. 18 at 10:01 PM

$HUMA buy as many as these cheap shares as you can now because down the road its going to payoff bigtime

0 · Reply

forgottenchuck Aug. 18 at 9:59 PM

$HUMA THIS VASCULAR SURGEON IS WORLD REKNOWN

0 · Reply

Market Cap	151.16M
Revenue (ttm)	2.04M
Net Income (ttm)	-40.83M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,001.47%
Debt to Equity Ratio	1.16

Volume	9,260,601
Avg Vol	11,758,100
Day's Range	N/A - N/A
Shares Out	269.64M
Stochastic %K	25%
Beta	2.54
Analysts	Strong Sell
Price Target	$1.79